First-line luspatercept for transfusion-dependent myelodysplastic neoplasms
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests whether luspatercept, given as the first treatment, can help people with a blood condition called myelodysplastic neoplasms who need regular red blood cell transfusions. It may reduce transfusion needs and improve blood counts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a diagnosis of myelodysplastic neoplasms (a blood disorder) that is classified as very low, low, or intermediate risk.
- You have needed at least 2 red blood cell transfusions in the 8 weeks before starting the trial treatment.
- Your doctor has decided that luspatercept is the right first treatment for you, based on the approved label.
- You are not currently receiving treatment for another cancer.
- You are not participating in another interventional (treatment) trial at the same time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies luspatercept to improve anemia (low red blood cells) in people with MDS that has a del5q change. It also checks safety, especially for people who need red blood cell transfusions and have not benefited from prior standard treatments.
This study tests a drug called luspatercept to see if it can improve anemia in people with rare inherited red blood cell disorders. It may help reduce the need for blood transfusions or raise hemoglobin levels.
This Phase 1/2 study tests luspatercept combined with another approach in people with low-risk myelodysplastic syndrome (MDS) who are not responding to or cannot use ESA (a common anemia treatment). It may help improve anemia (low hemoglobin), reduce transfusions, and control the disease if you fit the specific criteria.
This Phase 2 trial studies whether luspatercept can improve anemia in people with lower-risk myelodysplastic syndrome (MDS) who do not currently need red-blood-cell transfusions. It’s also looking to see if the benefit is similar whether or not you have ring sideroblasts.
This trial tests if luspatercept can help improve red blood cell counts in people with a certain type of acute myeloid leukemia (AML) who have mild to moderate anemia after intensive chemotherapy. It is for patients with a lower-risk form of AML who have completed 1–3 cycles of high-dose consolidation therapy.
This trial tests whether luspatercept can help improve low red blood cell counts (anemia) that happens soon after a stem cell transplant. It is for people with blood cancers who have very low hemoglobin after transplant.
Hear when a new Myelodysplastic Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.